Systemic mycosis

Summary

Systemic mycosis (MONDO:0000256) is a disease and 5 clinical trials. Top therapeutic interventions include voriconazole and posaconazole. A subtype of fungal infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	systemic mycosis
Mondo ID	MONDO:0000256
DOID	DOID:0050136
SNOMED CT	399314004
UMLS	C0553576
MedGen	639956
Is cancer (heuristic)	no

Also known as: systemic fungal infection

Disease family

This is a subtype of fungal infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › fungal infectious disease › systemic mycosis

Related subtypes (17): cutaneous mycosis, fungal esophagitis, opportunistic mycosis, fungal gastritis, fungal lung infectious disease, Pneumocystis infectious disease, sporotrichosis, fungal meningitis, fungal myositis, scedosporiosis, fungal infection of eye, mycotic endocarditis, mycotoxicosis, alternariosis, invasive scopulariopsis infection, emergomycosis, fungal discitis

Subtypes (3): primary systemic mycosis, disseminated sporotrichosis, opportunistic systemic mycosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	4
PHASE4	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02968134	PHASE4	COMPLETED	Single Dose Population Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients
NCT00721578	Not specified	COMPLETED	A Study Of Indian Patients Receiving Therapy For Systemic Fungal Infections
NCT01151085	Not specified	COMPLETED	Voriconazole (Vfend) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
NCT01686607	Not specified	COMPLETED	Short and Long-term Safety of Micafungin and Other Parenteral Antifungal Agents
NCT02492594	Not specified	COMPLETED	Optimized Diagnostics for Improved Therapy Stratification in Invasive Fungal Infections

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
VORICONAZOLE	4	2
POSACONAZOLE	4	1